• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Northwest, Medarex, Millennium Dealing Cancer Products, IP

Dec. 12, 2002
By Aaron Lorenzo

Structural GenomiX Enters Deal To Study Protein In Huntington's

Dec. 11, 2002
By Aaron Lorenzo
Looking to advance the discovery and development of therapeutics, Structural GenomiX Inc. and the Hereditary Disease Foundation entered a collaboration to use SGX's structure-directed drug discovery technologies to investigate the structure of the protein responsible for Huntington's disease. (BioWorld Today)
Read More

Structural GenomiX Enters Deal To Study Protein In Huntington's

Dec. 11, 2002
By Aaron Lorenzo
Looking to advance the discovery and development of therapeutics, Structural GenomiX Inc. and the Hereditary Disease Foundation entered a collaboration to use SGX's structure-directed drug discovery technologies to investigate the structure of the protein responsible for Huntington's disease. (BioWorld Today)
Read More

Idun Closes $22.8M Round, Goes Looking For $15M More

Dec. 10, 2002
By Aaron Lorenzo
Monday marked the start of a watershed week for Idun Pharmaceuticals Inc., which closed a $22.8 million preferred stock private placement financing concurrent with the Nobel Prize ceremony, at which the chairman of its scientific advisory board is being honored. (BioWorld Today)
Read More

Idun Closes $22.8M Round, Goes Looking For $15M More

Dec. 10, 2002
By Aaron Lorenzo
Monday marked the start of a watershed week for Idun Pharmaceuticals Inc., which closed a $22.8 million preferred stock private placement financing concurrent with the Nobel Prize ceremony, at which the chairman of its scientific advisory board is being honored. (BioWorld Today)
Read More

A Streamlining Curis Licenses Out PYY Technology For $15M

Dec. 9, 2002
By Aaron Lorenzo
Curis Inc. last week shed certain assets as part of an ongoing realignment, while licensing out its second program in about a week's time and simultaneously cutting jobs. (BioWorld Today)
Read More

A Streamlining Curis Licenses Out PYY Technology For $15M

Dec. 9, 2002
By Aaron Lorenzo
Curis Inc. last week shed certain assets as part of an ongoing realignment, while licensing out its second program in about a week's time and simultaneously cutting jobs. (BioWorld Today)
Read More

Developing Nicotinic Receptor Drugs, Targacept Raises $46M

Dec. 6, 2002
By Aaron Lorenzo
Its science rooted deep in North Carolina tobacco country, Targacept Inc. continues to impress observers with its neuronal nicotinic receptor approach to drug discovery. (BioWorld Today)
Read More

Developing Nicotinic Receptor Drugs, Targacept Raises $46M

Dec. 6, 2002
By Aaron Lorenzo
Its science rooted deep in North Carolina tobacco country, Targacept Inc. continues to impress observers with its neuronal nicotinic receptor approach to drug discovery. (BioWorld Today)
Read More

Ricerca Broadens Drug Program, Gains Lilly Antibacterial Targets

Dec. 5, 2002
By Aaron Lorenzo
View All Articles by Aaron Lorenzo

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 13, 2025.
  • Koreabio Humanase KOH Sungho

    FDA shift from animal testing fuels organoid, organ-on-chip demand

    BioWorld Science
    The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • Neuroplastin 65 knockout disrupts visual function by altering the retina

    BioWorld Science
    Researchers from Tongji University School of Medicine and collaborating institutions have discovered that NP65 plays a crucial role in maintaining normal visual...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe